← Back to TCM Global · All articles
2026-10-23
In June 2026, Giant Biogene (巨子生物, 02367.HK) announced that its self-developed ginsenoside CK had completed China's cosmetic new-ingredient registration — filing number 国妆原备字20260111. In China's regulatory system, this registration is widely seen as the critical node between laboratory science and a commercially usable active ingredient.
Ginsenoside CK (Compound K) is a rare saponin — it barely exists in raw ginseng and is mainly produced when gut bacteria metabolize common ginsenosides like Rb1. Research interest in CK centers on:
By registering CK specifically, Giant Biogene converted a research compound into a legally usable cosmetic ingredient — meaning formulas can now name it, dose it and market it within China's regulatory framework.
Giant Biogene is best known for recombinant collagen (brands Comfy/可复美 and Klijin/可丽金 generate most revenue). Its official positioning now lists rare ginsenosides alongside recombinant collagen as its two core technology directions — with reported hundred-kilogram-scale production of five high-purity rare saponins: Rk3, Rh4, Rk1, Rg5 and CK.
A registered CK ingredient means documented identity, purity and safety data exist in a government system. Sourcing conversations can move from 'trust me' to 'here is the registration number' — a materially better position for formulators and importers.
Cosmetic registration is the quiet milestone that industrializes a botanical active. With CK registered and four more rare saponins in its portfolio, Giant Biogene has turned ginseng chemistry into a regulated, scalable ingredient business — and the consumer products are only now beginning to follow.
Explore more Eastern wellness wisdom at TCM Global.